2seventy Bio Pauses Pediatric Blood Cancer Trial After Patient Death, Stock Plunges
Portfolio Pulse from Vandana Singh
2seventy Bio's Phase 1 trial of SC-DARIC33 in Acute Myeloid Leukemia (AML) has been paused by Seattle Children's after a fatal serious adverse event (SAE). The root cause of the SAE and its potential relationship to the study drug is under investigation. TSVT shares are down 11.90%.
June 14, 2023 | 2:37 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
2seventy Bio's stock plunges after the company's Phase 1 AML trial is paused due to a fatal SAE. The investigation into the root cause is ongoing.
The pause in the Phase 1 trial of SC-DARIC33 in AML due to a fatal SAE has led to a negative impact on 2seventy Bio's stock price. The ongoing investigation into the root cause of the SAE and its potential relationship to the study drug creates uncertainty for investors, resulting in a drop in the stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100